Esko is collaborating with Zacharon Pharmaceuticals, a San Diego - based biotechnology company, to
develop a commercial diagnostic assay for differentiating forms of MPS from urine and blood samples, a
screening test for
newborns and a tool for measuring the biochemical response of MPS patients to existing and novel therapies.